Your browser doesn't support javascript.
loading
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.
Joshi, Sunil K; Keck, Jamie M; Eide, Christopher A; Bottomly, Daniel; Traer, Elie; Tyner, Jeffrey W; McWeeney, Shannon K; Tognon, Cristina E; Druker, Brian J.
Afiliación
  • Joshi SK; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Keck JM; Department of Physiology & Pharmacology, School of Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Eide CA; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Bottomly D; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Traer E; Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, OR, USA.
  • Tyner JW; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • McWeeney SK; Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Tognon CE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Leukemia ; 34(10): 2798-2804, 2020 10.
Article en En | MEDLINE | ID: mdl-32366937
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia / Biomarcadores de Tumor / Transformación Celular Neoplásica / Receptor ErbB-2 / Mutación Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia / Biomarcadores de Tumor / Transformación Celular Neoplásica / Receptor ErbB-2 / Mutación Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article